retatrutide nz Beyond the GLP-1RA weight loss ceiling ADA26: retatrutide delivers unprecedented weight

PR Newswire / Eli Lilly press release (TRIUMPH-4 topline) (2025) 6

Clinical trials have shown that patients on Wegovy achieved an average weight loss of between 14.9% to 17.4% over 68 weeks when combined with healthier lifestyle choices

It is better described as more active at MC1R, rather than fully selective, since most melanocortin peptides can act on multiple receptors

See product images for documentation

These results suggest that Gs-cAMP signals are the main pathways for GLP-1 secretion in intestinal L-cells, in contrast to insulin secretion in pancreatic -cells (Fig

One key issue parents and physicians reported as a downside of the treatment was the physical administering of the actual injections themselves